[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA31093B1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA31093B1
MA31093B1 MA32087A MA32087A MA31093B1 MA 31093 B1 MA31093 B1 MA 31093B1 MA 32087 A MA32087 A MA 32087A MA 32087 A MA32087 A MA 32087A MA 31093 B1 MA31093 B1 MA 31093B1
Authority
MA
Morocco
Prior art keywords
fusion
protein
partner
proteins
antigen
Prior art date
Application number
MA32087A
Other languages
Arabic (ar)
English (en)
Inventor
Normand Blais
Denis Martin
Remi M Palmantier
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39300029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31093(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0700760A external-priority patent/GB0700760D0/en
Priority claimed from GB0701262A external-priority patent/GB0701262D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA31093B1 publication Critical patent/MA31093B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES PROTÉINES DE FUSION COMPRENANT UN ANTIGÈNE DÉRIVÉ DE L'ANTIGÈNE DIT DE REJET DES TUMEURS PRAME (ÉGALEMENT NOMMÉ DAGE) LIÉ À UN PARTENAIRE DE FUSION IMMUNOLOGIQUE QUI FOURNIT DES ÉPITOPES DE LYMPHOCYTES T AUXILIAIRES, TELS QUE, PAR EXEMPLE, LA PROTÉINE D DE HAEMOPHILUS INFLUENZAE B, DES PROTÉINES PARTENAIRES DE FUSION COMPRENANT DES FRAGMENTS DE LA PROTÉINE D, DES PROCÉDÉS POUR LEUR PRÉPARATION ET LA FORMULATION DE VACCINS AINSI QUE LEUR UTILISATION DANS LE TRAITEMENT DE TOUT UN ÉVENTAIL DE CANCERS.
MA32087A 2007-01-15 2009-07-10 Vaccin MA31093B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0700760A GB0700760D0 (en) 2007-01-15 2007-01-15 Vaccine
GB0701262A GB0701262D0 (en) 2007-01-23 2007-01-23 Vaccine
PCT/EP2008/050290 WO2008087102A1 (fr) 2007-01-15 2008-01-11 Vaccin

Publications (1)

Publication Number Publication Date
MA31093B1 true MA31093B1 (fr) 2010-01-04

Family

ID=39300029

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32087A MA31093B1 (fr) 2007-01-15 2009-07-10 Vaccin

Country Status (32)

Country Link
US (1) US20080187535A1 (fr)
EP (1) EP2114993B1 (fr)
JP (1) JP5391080B2 (fr)
KR (1) KR20090101313A (fr)
CN (1) CN101668770B (fr)
AR (1) AR064862A1 (fr)
AU (1) AU2008207025B2 (fr)
BR (1) BRPI0806463A2 (fr)
CA (1) CA2674552A1 (fr)
CL (1) CL2008000104A1 (fr)
CO (1) CO6210757A2 (fr)
CR (1) CR10971A (fr)
CY (1) CY1113760T1 (fr)
DK (1) DK2114993T3 (fr)
DO (1) DOP2009000167A (fr)
EA (1) EA016326B1 (fr)
ES (1) ES2393812T3 (fr)
HK (1) HK1138853A1 (fr)
HR (1) HRP20120828T1 (fr)
IL (1) IL199663A0 (fr)
JO (1) JO2840B1 (fr)
MA (1) MA31093B1 (fr)
MX (1) MX2009007571A (fr)
MY (1) MY153679A (fr)
NZ (1) NZ578285A (fr)
PE (2) PE20081686A1 (fr)
PL (1) PL2114993T3 (fr)
PT (1) PT2114993E (fr)
SI (1) SI2114993T1 (fr)
TW (1) TWI434697B (fr)
WO (1) WO2008087102A1 (fr)
ZA (1) ZA200904923B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398492T3 (es) * 2007-01-15 2013-03-19 Glaxosmithkline Biologicals Sa Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
KR20120002534A (ko) 2009-03-17 2012-01-05 엠디엑스헬스 에스에이 유전자 발현의 향상된 검출
CA2763492A1 (fr) * 2009-06-05 2010-12-09 The Ohio State University Research Foundation Biomateriaux, compositions, et procedes
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
EP2734539A1 (fr) 2011-07-22 2014-05-28 GlaxoSmithKline Biologicals S.A. Purification de prame
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
RU2590701C2 (ru) * 2013-04-29 2016-07-10 Общество с ограниченной ответственностью "ГеноТехнология" Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка
US20160367651A1 (en) 2013-10-01 2016-12-22 Mie University T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
CN105254767A (zh) * 2015-11-17 2016-01-20 重庆科润生物医药研发有限公司 一种Protein D与HER2融合蛋白及其制备方法和应用
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别源自于prame抗原短肽的tcr
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr及其相关组合物
WO2019061297A1 (fr) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 Peptide de fusion d'épitope de lymphocyte t auxiliaire cd4 et vaccin associé
MX2020004829A (es) * 2017-11-08 2020-11-11 Advaxis Inc Péptidos heteroclíticos inmunogénicos de proteínas asociadas al cáncer y métodos de uso de los mismos.
CN109879957B (zh) * 2017-12-06 2022-03-18 香雪生命科学技术（广东）有限公司 针对prame的高亲和力t细胞受体
WO2021243295A2 (fr) * 2020-05-29 2021-12-02 Children's National Medical Center Identification d'épitopes peptidiques de prame restreints par hla, lymphocytes t spécifiques de prame appropriés pour le traitement standard d'un cancer exprimant prame
CA3217738A1 (fr) 2021-05-05 2022-05-04 Immatics Biotechnologies Gmbh Proteines de liaison a l'antigene se liant de maniere specifique a prame

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
KR100372375B1 (ko) * 1993-12-23 2003-04-21 머클한스피터 면역반응의강화방법
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ATE462788T1 (de) * 1998-02-05 2010-04-15 Glaxosmithkline Biolog Sa Verfahren zur reinigung oder herstellung der mage protein
CA2363118A1 (fr) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogenes comprenant un peptide et support derive de haemophilius influenzae
ES2250151T3 (es) * 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. Uso de cpg como adyuvante de vacuna contra vih.
US6495347B1 (en) * 1999-07-08 2002-12-17 Stressgen Biotechnologies Corporation Induction of a Th1-like response in vitro

Also Published As

Publication number Publication date
PT2114993E (pt) 2012-11-28
IL199663A0 (en) 2010-04-15
TW200902048A (en) 2009-01-16
WO2008087102A1 (fr) 2008-07-24
MX2009007571A (es) 2009-07-22
DK2114993T3 (da) 2012-10-22
CR10971A (es) 2009-09-09
US20080187535A1 (en) 2008-08-07
KR20090101313A (ko) 2009-09-24
EP2114993B1 (fr) 2012-08-29
SI2114993T1 (sl) 2012-12-31
BRPI0806463A2 (pt) 2011-09-06
PL2114993T3 (pl) 2013-01-31
JO2840B1 (en) 2014-09-15
CL2008000104A1 (es) 2008-07-18
CN101668770A (zh) 2010-03-10
JP5391080B2 (ja) 2014-01-15
AU2008207025A1 (en) 2008-07-24
EA016326B1 (ru) 2012-04-30
CO6210757A2 (es) 2010-10-20
CA2674552A1 (fr) 2008-07-24
TWI434697B (zh) 2014-04-21
EP2114993A1 (fr) 2009-11-11
CN101668770B (zh) 2013-06-12
MY153679A (en) 2015-03-13
EA200900795A1 (ru) 2010-02-26
AU2008207025B2 (en) 2012-08-23
CY1113760T1 (el) 2016-07-27
DOP2009000167A (es) 2009-07-15
PE20130324A1 (es) 2013-03-05
ZA200904923B (en) 2012-12-27
HRP20120828T1 (hr) 2012-11-30
AR064862A1 (es) 2009-04-29
PE20081686A1 (es) 2008-12-25
JP2010515444A (ja) 2010-05-13
NZ578285A (en) 2011-12-22
HK1138853A1 (en) 2010-09-03
ES2393812T3 (es) 2012-12-28

Similar Documents

Publication Publication Date Title
MA31093B1 (fr) Vaccin
Rivoltini et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma-and colon carcinoma-specific T cells
Hoffmann et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53264–272 peptide in the circulation of patients with head and neck cancer
Scally et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis
Chapman et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin+ QS21 vaccine: a dose-response study
Shams et al. Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles
Carbone et al. Immunization with mutant p53-and K-ras–derived peptides in cancer patients: immune response and clinical outcome
Manjili et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110
MA43461B1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
Wald et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons
Udono et al. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70
Smith et al. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells
MA43328B2 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
KR20180006945A (ko) 암 치료 및 예방용 백신
Tobian et al. Mycobacterium tuberculosis heat shock fusion protein enhances class I MHC cross-processing and-presentation by B lymphocytes
Zwaveling et al. Antitumor efficacy of wild-type p53-specific CD4+ T-helper cells
WO2016176624A3 (fr) Pestivirus porcin, vaccins et dosages
MA43794A (fr) Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie
Perez et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu (776–790) hybrid peptide vaccine in patients with prostate cancer
He et al. Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model
Wong et al. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma
Pawaria et al. A role for the heat shock protein–CD91 axis in the initiation of immune responses to tumors
Besneux et al. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design
Suryadevara et al. Immunotherapy gone viral: bortezomib and oHSV enhance antitumor NK-cell activity
Melief Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine